CoChat

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

Stein, E. A., Giugliano, R. P., Koren, M. J., Raal, F. J., Roth, E. M., Weiss, R., Sullivan, D., Wasserman, S. M., Somaratne, R., Kim, J. B., Yang, J., Liu, T., Albizem, M., Scott, R., Sabatine, M. S., for the PROFICIO Investigators · 2014 · European Heart Journal

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

AIMS: Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9 (PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However, the ability to detect potentially beneficial changes in other lipoproteins such as lipoprotein (a), triglycerides, high-density lipoprotein cholesterol (HDL-C), and apolipoprotein (Apo) A1, and adverse events (AEs) was limited by sample sizes of individual trials. We report a pooled analysis from four phase 2 studies of evolocumab (AMG 145), a monoclonal antibody to PCSK9. METHODS AND RESULTS: The trials randomized 1359 patients to various doses of subcutaneous evolocumab every 2 weeks (Q2W) or 4 weeks (Q4W), placebo, or ezetimibe for 12 weeks; 1252 patients contributed to efficacy and 1314, to safety analyses. Mean percentage (95% CI) reductions in LDL-C vs. placebo ranged from 40.2% (44.6%, 35.8%) to 59.3% (63.7%, 54.8%) among the evolocumab groups (all P < 0.001). Statistically significant reductions in apolipoprotein B (Apo B), non-high-density lipoprotein cholesterol (non-HDL-C), triglycerides and lipoprotein (a) [Lp(a)], and increases in HDL-C were also observed. Adverse events (AEs) and serious AEs with evolocumab were reported in 56.8 and 2.0% of patients, compared with 49.2% and 1.2% with placebo. Adjudicated cardiac and cerebrovascular events were reported in 0.3 and 0% in the placebo and 0.9 and 0.3% in the evolocumab arms, respectively. CONCLUSION: In addition to LDL-C reduction, evolocumab, dosed either Q2W or Q4W, demonstrated significant and favourable changes in other atherogenic and anti-atherogenic lipoproteins, and was well tolerated over the 12-week treatment period.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu085

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. 2011, Atherosclerosis, 217, S1

Cited by

See all 135

Metadata

Authors
Stein, E. A., Giugliano, R. P., Koren, M. J., Raal, F. J., Roth, E. M., Weiss, R., Sullivan, D., Wasserman, S. M., Somaratne, R., Kim, J. B., Yang, J., Liu, T., Albizem, M., Scott, R., Sabatine, M. S., & for the PROFICIO Investigators
Affiliations
  • Brigham and Women's Hospital (US)
  • Jacksonville Center for Clinical Research (US)
  • University of the Witwatersrand (ZA)
  • Sterling Research Group (US)
  • Maine Research Associates (US)
  • Royal Prince Alfred Hospital (AU)
  • Amgen (United States) (US)
Corresponding author
Stein, E. A.
Venue
European Heart Journal
Published
2014-03-04
Volume
35
Issue
33
Pages
2249-2259
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2124565608
Cited by
130
References
29
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 1 · 2021: 5 · 2020: 8 · 2019: 10 · 2018: 15 · 2017: 19 · 2016: 24 · 2015: 27 · 2014: 7
FWCI
25.43
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Sanofi
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
evolocumab, PCSK9 inhibition, hyperlipidemia, LDL cholesterol lowering, apolipoprotein B, lipoprotein(a), triglycerides, HDL cholesterol, non-HDL cholesterol, ezetimibe, dosing frequency, adverse events, atherogenic lipoproteins, lipid-lowering therapy, pooled analysis, cardiovascular safety
MeSH terms
Ezetimibe, Proprotein Convertase 9, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Azetidines, Female, Humans, Hyperlipidemias, Male, Middle Aged, Serine Endopeptidases, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase II as Topic, Proprotein Convertases, Lipid Metabolism, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. https://app.cochat.ai/papers/10.1093/eurheartj/ehu085
The paper
Stein, E. A., Giugliano, R. P., Koren, M. J., Raal, F. J., Roth, E. M., Weiss, R., Sullivan, D., Wasserman, S. M., Somaratne, R., Kim, J. B., Yang, J., Liu, T., Albizem, M., Scott, R., Sabatine, M. S., & for the PROFICIO Investigators. (2014). Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.